A Study of Two Different Formulations of LY3074828 in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-30

Study Completion Date

2017-11-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations. The tolerability of LY3074828 will also be evaluated and information about any side effects experienced will be collected.

Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be approximately 13 weeks, not including screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Two Formulations of LY3074828 in Healthy Participants

NCT03662100

Healthy

COMPLETED PHASE1

A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants

NCT03220126

Healthy

COMPLETED PHASE1

A Study of How the Body Absorbs LY3537031

NCT07202871

Healthy

ACTIVE_NOT_RECRUITING PHASE1

A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children

NCT02370485

Healthy

COMPLETED PHASE1

A Study of LY3866288 in Healthy Participants

NCT06641037

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Reference: 250 mg LY3074828

250 mg LY3074828 lyophilized formulation administered subcutaneously (SC) as 3 injections

Group Type EXPERIMENTAL

LY3074828

Intervention Type BIOLOGICAL

Administered SC

Test 1: 250 mg LY3074828

250 mg LY3074828 solution formulation administered as SC injections in two prefilled syringes

Group Type EXPERIMENTAL

LY3074828

Intervention Type BIOLOGICAL

Administered SC

Test 2: 500 mg LY3074828

500 mg LY3074828 solution formulation administered as SC injections in four prefilled syringes

Group Type EXPERIMENTAL

LY3074828

Intervention Type BIOLOGICAL

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3074828

Administered SC

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Must not have an average weekly alcohol intake that exceeds 21 units/week (males) and 14 units/week (females)
* Must not show evidence of active or latent tuberculosis (TB)
* Must not have received live vaccine(s) (including attenuated live vaccines and those administered intranasally) within 1 month of screening, or intend to during the study
* Must not have been treated with steroids within 1 month of screening, or intend to during the study
* Must not be immunocompromised
* Must not have received treatment with biologic agents (e.g. monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to Day 1
* Must not have significant allergies to humanised monoclonal antibodies
* Must not have clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or sever post treatment hypersensitivity reactions
* Must not have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years
* Must not have had breast cancer within the past 10 years

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes